同類(lèi)產(chǎn)品
達(dá)比加群酯雜質(zhì)新藥申報(bào)用
達(dá)比加群酯是zui前沿的新一代口服抗凝藥物直接凝血酶抑制劑(DTIs),用于預(yù)防非瓣膜性房顫患者的卒中和全身性栓塞。達(dá)比加群酯可提供有效的、可預(yù)測(cè)的、穩(wěn)定的抗凝效果,同時(shí)較少發(fā)生藥物相互作用,無(wú)藥物食物相互作用,無(wú)需常規(guī)進(jìn)行凝血功能監(jiān)測(cè)或劑量調(diào)整。
深圳遠(yuǎn)揚(yáng)化學(xué)可提供達(dá)比加群酯申報(bào)所用全套雜質(zhì), 進(jìn)口國(guó)產(chǎn)均有銷(xiāo)售,隨貨附CoA證書(shū),HNMR,MS,HPLC圖譜,純度符合申報(bào)要求。另外,我司有自主實(shí)驗(yàn)室,可提供達(dá)比加群酯雜質(zhì)定制服務(wù),如以上列表無(wú)您需要的雜質(zhì),我司詳詢(xún)(請(qǐng)點(diǎn)擊本頁(yè)標(biāo)題下方,進(jìn)入該公司展臺(tái)查看我司信息)。
Dabigatran | 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid | C25H25N7O3 | 471.51 |
Dabigatran Impurity 1 | ethyl 3-(2-(iminomethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C20H21N5O3 | 379.41 |
Dabigatran Impurity 2 | 3-(2-(((4-(N-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid | C32H37N7O5 | 599.68 |
Dabigatran Impurity 3 | ethyl 3-(1-methyl-3-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamido)propanoate | C20H22N4O4 | 382.41 |
Dabigatran Impurity 4 | methyl 3-(2-(hydroxymethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C19H20N4O4 | 368.39 |
Dabigatran Impurity 5 | 3-(2-(chloromethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid | C18H17ClN4O3 | 372.81 |
Dabigatran Impurity 6 | diethyl 3,3'-((2,2'-(oxybis(methylene))bis(1-methyl-1H-benzo[d]imidazole-5,5'-carbonyl))bis(pyridin-2-ylazanediyl))dipropanoate | C40H42N8O7 | 746.32 |
Dabigatran Impurity 7 | hexyl (imino(4-(((1-methyl-5-(pyridin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)methyl)amino)phenyl)methyl)carbamate | C29H33N7O3 | 527.62 |
Dabigatran Impurity 8 | (Z)-3-(2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid | C32H37N7O5 | 599.68 |
Dabigatran Impurity 9 | ethyl 3-(2-(((4-(((hexyloxy)carbonyl)carbamoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C34H40N6O6 | 628.72 |
Dabigatran Impurity 10 | (Z)-ethyl 3-(2-(((4-(N'-((hexan-2-yloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C34H41N7O5 | 627.73 |
Dabigatran Impurity 11 | (Z)-ethyl 3-(2-(((4-(N'-((hexan-3-yloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C34H41N7O5 | 627.73 |
Dabigatran Impurity 12 | ethyl 3-(1,2-dimethyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C20H22N4O3 | 366.41 |
Dabigatran Impurity 13 | ethyl 3-(1-methyl-2-oxo-N-(pyridin-2-yl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamido)propanoate | C19H20N4O4 | 368.39 |
Dabigatran Impurity 14 | (Z)-ethyl 2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-1H-benzo[d]imidazole-5-carboxylate | C26H33N5O4 | 479.57 |
Dabigatran Impurity 15 | ethyl 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C27H26N6O3 | 482.53 |
Dabigatran Impurity 16 | ethyl 3-(2-(((4-(ethoxy(imino)methyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride | C29H32N6O4·HCl | 565.06 |
Dabigatran Impurity 17 | (Z)-methyl 3-(2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C33H39N7O5 | 613.71 |
Dabigatran Impurity 18 | (Z)-hexyl (amino(4-(((5-((3-amino-3-oxopropyl)(pyridin-2-yl)carbamoyl)-1-methyl-1H-benzo[d]imidazol-2-yl)methyl)amino)phenyl)methylene)carbamate | C32H38N8O4 | 598.70 |
Dabigatran Impurity 19 | ethyl 3-(2-(((4-carbamoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C27H28N6O4 | 500.55 |
Dabigatran Impurity 20 | ethyl 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride | C27H29N7O3·HCl | 536.03 |
Dabigatran Impurity 21 | ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate | C18H22N4O3 | 342.39 |
Dabigatran Impurity 22 | ethyl 3-(3-(2-((4-cyanophenyl)amino)acetamido)-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate | C27H28N6O4 | 500.55 |
達(dá)比加群酯雜質(zhì)新藥申報(bào)用結(jié)構(gòu)式歡迎我司獲取~
相關(guān)產(chǎn)品
免責(zé)聲明
- 凡本網(wǎng)注明“來(lái)源:化工儀器網(wǎng)”的所有作品,均為浙江興旺寶明通網(wǎng)絡(luò)有限公司-化工儀器網(wǎng)合法擁有版權(quán)或有權(quán)使用的作品,未經(jīng)本網(wǎng)授權(quán)不得轉(zhuǎn)載、摘編或利用其它方式使用上述作品。已經(jīng)本網(wǎng)授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來(lái)源:化工儀器網(wǎng)”。違反上述聲明者,本網(wǎng)將追究其相關(guān)法律責(zé)任。
- 本網(wǎng)轉(zhuǎn)載并注明自其他來(lái)源(非化工儀器網(wǎng))的作品,目的在于傳遞更多信息,并不代表本網(wǎng)贊同其觀點(diǎn)和對(duì)其真實(shí)性負(fù)責(zé),不承擔(dān)此類(lèi)作品侵權(quán)行為的直接責(zé)任及連帶責(zé)任。其他媒體、網(wǎng)站或個(gè)人從本網(wǎng)轉(zhuǎn)載時(shí),必須保留本網(wǎng)注明的作品第一來(lái)源,并自負(fù)版權(quán)等法律責(zé)任。
- 如涉及作品內(nèi)容、版權(quán)等問(wèn)題,請(qǐng)?jiān)谧髌钒l(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系,否則視為放棄相關(guān)權(quán)利。